MARK N LAMPERT
CIK 1233840 · last filed 2023-11-06
MARK N LAMPERT is a corporate insider who has filed 42 SEC Form 4 insider transactions across 23 companies since 2009. The most recent filing shows the insider bought $53.0M of KYMR on Nov 6, 2023. Across all open-market trades the lifetime net is +$37.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.56B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.56B
23
42
$37.95M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 2,552,306 | $106.16 | $270.95M | $53.01M | 1 | 2023-11-06 |
| OLMA | Director | 3,913,676 | $11.62 | $45.48M | $0 | 1 | 2023-06-21 |
| XOMAP | Director | 1,989,844 | $24.98 | $49.71M | $4.21M | 1 | 2023-01-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 3,350,950 | $2.65 | $8.88M | $35.70M | 1 | 2022-05-20 |
| CGEM | 10%+ Owner | 2,196,240 | $17.47 | $38.37M | $29.67M | 1 | 2022-04-05 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 4,611,909 | $38.00 | $175.25M | $21.84M | 1 | 2020-11-06 |
| Principia Biopharma Inc. (PRNB) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2020-08-20 |
| Calithera Biosciences, Inc. (CALA) Delisted | 10%+ Owner | 185,617 | $0.00 | $56 | -$90.66M | 2 | 2020-05-26 |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 1,804,105 | $90.00 | $162.37M | $31.51M | 1 | 2020-01-21 |
| XOMA | 10%+ Owner | 1,335,192 | $40.17 | $53.63M | $57.47M | 1 | 2019-12-20 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 5,289 | $15.70 | $83.0K | $37.17M | 1 | 2019-09-09 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,510,597 | $0.04 | $291.0K | $21.70M | 2 | 2018-11-30 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 10%+ Owner | 951,300 | $8.37 | $7.96M | -$239.32M | 1 | 2017-12-21 |
| CAPS | 10%+ Owner | 0 | $0.25 | $0 | -$1.06M | 5 | 2017-07-18 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 10%+ Owner | 277,314 | — | — | $1.03M | 2 | 2017-06-22 |
| XENE | 10%+ Owner | 1,018,197 | $64.94 | $66.12M | $10.27M | 2 | 2017-06-19 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 2,218,076 | — | — | $0 | 1 | 2016-06-27 |
| CCXI | 10%+ Owner | 2,671,577 | $14.52 | $38.79M | $40.29M | 4 | 2015-11-05 |
| RIGL | 10%+ Owner | 79,962 | $38.50 | $3.08M | $680.4K | 1 | 2013-06-11 |
| LGND | 10%+ Owner | 741,627 | $296.28 | $219.73M | $35.05M | 4 | 2012-11-19 |
| NBIX | 10%+ Owner | 8,847,147 | $182.83 | $1.62B | -$647.3K | 2 | 2011-10-14 |
| Astex Pharmaceuticals, Inc (SUPG) Delisted | 10%+ Owner | 11,270,798 | — | — | -$3.63M | 1 | 2010-04-21 |
| RPRX | 10%+ Owner | 2,577,026 | $59.97 | $154.54M | -$6.35M | 2 | 2009-09-16 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-06 | KYMR | Buy (P) | +4,141,050 | $53.01M | EDGAR |
| 2023-06-21 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2023-01-09 | XOMAP | Buy (P) | +222,490 | $4.21M | EDGAR |
| 2022-05-20 | Repare Therapeutics Inc. (RPTX) Delisted | Buy (P) | +4,200,000 | $35.70M | EDGAR |
| 2022-04-05 | CGEM | Buy (P) | +2,760,000 | $29.67M | EDGAR |
| 2020-11-06 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +4,465,620 | $21.84M | EDGAR |
| 2020-08-20 | Principia Biopharma Inc. (PRNB) Delisted | Buy (P) | — | $0 | EDGAR |
| 2020-05-26 | Calithera Biosciences, Inc. (CALA) Delisted | Sell (S) | −15,985,186 | -$95.91M | EDGAR |
| 2020-01-21 | Merus N.V. (MRUS) Delisted | Buy (P) | +1,951,110 | $31.51M | EDGAR |
| 2019-12-20 | XOMA | Mixed | +5,918,241 | $130.20M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.